Quantitative analysis of survivin mRNA expression in urine and tumor tissue of bladder cancer patients and its potential relevance for disease detection and prognosis

2005 ◽  
Vol 116 (1) ◽  
pp. 100-104 ◽  
Author(s):  
Steffen Weikert ◽  
Frank Christoph ◽  
Mark Schrader ◽  
Hans Krause ◽  
Kurt Miller ◽  
...  
Keyword(s):  
Bladder Cancer ◽  
Quantitative Analysis ◽  
Mrna Expression ◽  
Cancer Patients ◽  
Tumor Tissue ◽  
Disease Detection ◽  
Survivin Mrna

319Quantitative survivin mRNA expression in tumour tissue and urine of bladder cancer patients

2005 ◽  
Vol 4 (3) ◽  
pp. 82
Author(s):  
S. Weikert ◽  
F. Christoph ◽  
H. Krause ◽  
M. Mueller ◽  
C. Kempkensteffen ◽  
...  
Keyword(s):  
Bladder Cancer ◽  
Mrna Expression ◽  
Cancer Patients ◽  
Tumour Tissue ◽  
Survivin Mrna

955: Quantitative Survivin mRNA Expression In Tumour Tissue and Urine of Bladder Cancer Patients

2004 ◽  
Vol 171 (4S) ◽  
pp. 253-253
Author(s):  
Steffen Weikert ◽  
Markus Mueller ◽  
Frank Christoph ◽  
Hans Krause ◽  
Kurt Miller
Keyword(s):  
Bladder Cancer ◽  
Mrna Expression ◽  
Cancer Patients ◽  
Tumour Tissue ◽  
Survivin Mrna

Correlation between anti-survivin antibody and survivin mRNA expression in head and neck cancer patients

2010 ◽  
Vol 130 (8) ◽  
pp. 959-965 ◽  
Author(s):  
Naoki Uemura ◽  
Satoru Kodama ◽  
Nozomi Nomi ◽  
Tomoyo Okamoto ◽  
Masashi Suzuki
Keyword(s):  
Head And Neck Cancer ◽  
Head And Neck ◽  
Mrna Expression ◽  
Cancer Patients ◽  
Neck Cancer ◽  
Survivin Mrna

XIAP mRNA levels but not XAF1 or XIAP/XAF1 mRNA levels predict pathological response in bladder cancer patients treated with neoadjuvant chemotherapy

2006 ◽  
Vol 24 (18_suppl) ◽  
pp. 20030-20030
Author(s):  
M. B. Pinho ◽  
J. Sellos ◽  
F. Costas ◽  
D. Herchenhorn ◽  
F. A. Peixoto ◽  
...  
Keyword(s):  
Bladder Cancer ◽  
Mrna Expression ◽  
Cancer Patients ◽  
Pathological Response ◽  
Negative Regulator ◽  
Inhibitor Of Apoptosis ◽  
Mrna Levels ◽  
Bivariate Correlation ◽  
Xiap Expression

20030 Background: The relation between apoptosis-related molecules and chemosensitivity has been extensively studied. In recent years, attention has shifted to a new family of inhibitor of apoptosis proteins (IAPs). XIAP (X- linked inhibitor of apoptosis) is the most versatile and potent member of the IAP family. To date, the overexpression of XIAP has been detected in various cancers. XAF1 (X-linked inhibitor of apoptosis associated factor 1) is a new protein identified for its ability to interact with XIAP. Neither XIAP nor XAF1 or XIAP/XAF1 mRNA expression have been studied in bladder cancer patients. Methods: The expression of XIAP and XAF1 mRNA was analyzed by a real time quantitative fluorogenic PCR method in a group of 17 patients with locally advanced bladder cancer treated with a combination of neoadjuvant Gemcitabine and Cisplatin. The prognostic significance of XIAP and XAF1 mRNA expression and the correlation with several clinicopathological variables was evaluated. Results: XIAP and XAF1 mRNA expression was detected in all 17 (100%) case samples. The levels of XIAP mRNA expression showed a moderate variation among samples. In contrast, XAF1 and XIAP/XAF1 mRNA levels showed significant variation among samples. Bivariate correlation analyses revealed a significant positive Spearman direct correlation coefficient between the XIAP expression and the pathological response. No significant correlation was found for XAF1 expression as well as for the XIAP/XAF1 ratio and clinical and pathological response. Conclusions: This is first study to address the role of XIAP, its negative regulator XAF1, and the XIAP/XAF1 ratio in bladder cancer patients. The positive correlation between the XIAP mRNA expression and the pathological response is in line with a previous study from our group in which a correlation was found between XIAP expression and survival. All these observations point to a complex role of XIAP in tumor biology. XAF1 mRNA expression in bladder carcinomas did not achieve significance as an independent predictive and prognostic factor in a bivariate analysis. Further studies are necessary in order to better assess a possible clinical value for XIAP and XAF1 as predictive and prognostic markers in cancer patients. No significant financial relationships to disclose.

scholarly journals TAK1 mRNA Expression in the Tumor Tissue of Locally Advanced Head and Neck Cancer Patients

2008 ◽  
Vol 2 ◽  
pp. 117762500800200
Author(s):  
Beatriz Honorato ◽  
Juan Alcalde ◽  
Rafael Martinez-Monge ◽  
Natalia Zabalegui ◽  
Jesús Garcia-Foncillas
Keyword(s):  
Head And Neck Cancer ◽  
Head And Neck ◽  
Mrna Expression ◽  
Cancer Patients ◽  
Neck Cancer ◽  
Tumor Tissue ◽  
Locally Advanced ◽  
Advanced Head

scholarly journals Genomic alterations and abnormal expression of APE2 in multiple cancers

2020 ◽  
Author(s):  
Katherine A. Jensen ◽  
Xinghua Shi ◽  
Shan Yan
Keyword(s):  
Dna Repair ◽  
Mrna Expression ◽  
Cancer Patients ◽  
Tumor Tissue ◽  
Excision Repair ◽  
The Cancer Genome Atlas ◽  
Genomic Alterations ◽  
Abnormal Expression ◽  
Multiple Cancers ◽  
Cancer Types

AbstractAlthough APE2 plays essential roles in base excision repair and ATR-Chk1 DNA damage response (DDR) pathways, it remains unknown how the APE2 gene is altered in the human genome and whether APE2 is differentially expressed in cancer patients. Here, we report multiple-cancer analyses of APE2 genomic alterations and mRNA expression from cancer patients using available data from The Cancer Genome Atlas (TCGA). We observe that APE2 genomic alterations occur at ~17% frequency in 14 cancer types (n= 21,769). Most frequent somatic mutations of APE2 appear in uterus (2.89%) and skin (2.47%) tumor samples. Furthermore, APE2 expression is upregulated in tumor tissue compared with matched non-malignant tissue across 5 cancer types including kidney, breast, lung, liver, and uterine cancers, but not in prostate cancer. We also examine the mRNA expression of 13 other DNA repair and DDR genes from matched samples for 6 cancer types. We show that APE2 mRNA expression is positively correlated with PCNA, APE1, XRCC1, PARP1, Chk1, and Chk2 across these 6 tumor tissue types; however, groupings of other DNA repair and DDR genes are correlated with APE2 with different patterns in different cancer types. Taken together, this study demonstrates alterations and abnormal expression of APE2 from multiple cancers.

mRNA expression levels of the biological factors uPAR, uPAR-del4/5, and rab31, displaying prognostic value in breast cancer, are not clinically relevant in advanced ovarian cancer

2011 ◽  
Vol 392 (11) ◽  
Author(s):  
Matthias Kotzsch ◽  
Julia Dorn ◽  
Kristina Doetzer ◽  
Barbara Schmalfeldt ◽  
Janna Krol ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Ovarian Cancer ◽  
Mrna Expression ◽  
Cancer Patients ◽  
Prognostic Value ◽  
Tumor Tissue ◽  
Advanced Ovarian Cancer ◽  
Biological Factors ◽  
Expression Levels ◽  
Mrna Expression Levels

Abstract High tumor tissue mRNA expression of the tumor biological factors uPAR, uPAR-del4/5, or rab31 is associated with shorter distant metastasis-free and overall survival in breast cancer patients. To evaluate whether these factors are also clinically relevant in ovarian cancer, we quantified the respective mRNA levels in primary tumor tissue of advanced ovarian cancer patients (n=103) and evaluated their association with clinicopathological parameters and patients’ prognosis. mRNA expression levels of all three markers did not show any significant association with overall or progression-free survival, demonstrating that these factors have no prognostic value in advanced ovarian cancer.

scholarly journals Characterization of kallikrein-related peptidase 4 (KLK4) mRNA expression in tumor tissue of advanced high-grade serous ovarian cancer patients

PLoS ONE ◽  
2019 ◽  
Vol 14 (2) ◽  
pp. e0212968 ◽  
Author(s):  
Weiwei Gong ◽  
Yueyang Liu ◽  
Christof Seidl ◽  
Tobias Dreyer ◽  
Enken Drecoll ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Mrna Expression ◽  
Cancer Patients ◽  
Tumor Tissue ◽  
High Grade ◽  
Serous Ovarian Cancer

Overexpression of Human Chorionic Gonadotropin β Genes 3, 5 and 8 in Tumor Tissue and Urinary Cells of Bladder Cancer Patients

Tumor Biology ◽  
2007 ◽  
Vol 28 (1) ◽  
pp. 52-56 ◽  
Author(s):  
Kristina Hotakainen ◽  
Susanna Lintula ◽  
Riikka Järvinen ◽  
Annukka Paju ◽  
Jakob Stenman ◽  
...  
Keyword(s):  
Bladder Cancer ◽  
Cancer Patients ◽  
Chorionic Gonadotropin ◽  
Human Chorionic Gonadotropin ◽  
Tumor Tissue ◽  
Human Chorionic Gonadotropin Beta
Sign in / Sign up

Export Citation Format

Share Document